Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-06-02T03:54:41.429Z Has data issue: false hasContentIssue false
  • English
  • Français

Monitoring of acetyl salicylic acid-induced platelet inhibition with impedance aggregometry in children with systemic-to-pulmonary shunts

Published online by Cambridge University Press:  12 June 2012

Birgitta S. Romlin ,
Håkan Wåhlander ,
Eva Strömvall-Larsson ,
Mats Synnergren ,
Fariba Baghaei  and
Anders Jeppsson
Birgitta S. Romlin*
Affiliation:
Department of Paediatric Anaesthesia and Intensive Care, Queen Silvia's Children Hospital, Gothenburg, Sweden
Håkan Wåhlander
Affiliation:
Department of Paediatric Cardiology, Queen Silvia's Children Hospital, Gothenburg, Sweden
Eva Strömvall-Larsson
Affiliation:
Department of Paediatric Cardiology, Queen Silvia's Children Hospital, Gothenburg, Sweden
Mats Synnergren
Affiliation:
Department of Cardiovascular Surgery and Anesthesia, Sahlgrenska University Hospital, Gothenburg, Sweden
Fariba Baghaei
Affiliation:
Department of Medicine/Haematology and Coagulation Disorders, Sahlgrenska University Hospital, Gothenburg, Sweden
Anders Jeppsson
Affiliation:
Department of Cardiovascular Surgery and Anesthesia, Sahlgrenska University Hospital, Gothenburg, Sweden Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
*
Correspondence to: Dr B. S. Romlin, MD, Department of Paediatric Anaesthesia and Intensive Care, Queen Silvia's Children Hospital, 416 85 Gothenburg, Sweden. Tel: +46-31-3434000; Fax +46-31-343 58 80; E-mail: birgitta.romlin@vgregion.se
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Shunt thrombosis after implantation of systemic-to-pulmonary shunts in paediatric patients is common. Acetyl salicylic acid is used for anti-thrombotic treatment; however, the effect is rarely monitored, although it is known that the response varies. The aim was to determine the effects of acetyl salicylic acid medication on platelet aggregation in children with systemic-to-pulmonary shunts.

Methods

A total of 14 children – median age 12 days; ranging from 3 to 100 days – were included in a prospective observational longitudinal study. All children were treated with oral acetyl salicylic acid (3–5 milligrams per kilogram once daily) after shunt implantation. Acetyl salicylic acid-dependent platelet aggregation in whole blood was analysed with impedance aggregometry (Multiplate®) after addition of arachidonic acid. Analyses were carried out before the primary operation, before and 5 and 24 hours after the first acetyl salicylic acid dose, and after 3–6 months of treatment. The therapeutic range for acetyl salicylic acid was defined as a test result less than 60 units.

Results

Acetyl salicylic acid reduced the arachidonic acid-induced platelet aggregation in all but one patient. Of the patients, 93% were in the therapeutic range 5 hours after acetyl salicylic acid intake, 86% were in the range after 24 hours, and 64% after 3–6 months.

Conclusions

Acetyl salicylic acid reduces platelet aggregation after shunt implantation in paediatric patients, but a considerable percentage of the children are outside the therapeutic range. Monitoring of platelet aggregation has the potential to improve anti-platelet treatment after shunt implantation by identifying children with impaired acetyl salicylic acid response.

Keywords

Aspirinpaediatric cardiac surgerythrombosisplateletsplatelet aggregationaspirin resistance
Type
Original Article
Information
Cardiology in the Young , Volume 23 , Issue 2 , April 2013 , pp. 225 - 232
Copyright
Copyright © Cambridge University Press 2012 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Li, JS, Yow, E, Berezny, KY. Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease. Circulation 2007; 116: 293–297.Google Scholar
2. Cholette, JM, Rubenstein, JS, Alfieris, GM, et al. Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery. Ann Thorac Surg 2007; 84: 1320–1325.CrossRefGoogle ScholarPubMed
3. Vane, JR, Botting, RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255–258.CrossRefGoogle ScholarPubMed
4. Angiolillo, DJ, Fernandez-Ortiz, A, Bernardo, E, et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006; 97: 38–43.CrossRefGoogle ScholarPubMed
5. Coakley, M, Self, R, Marchant, W, Mackie, I, Mallet, SV, Mythen, M. Use of the platelet function analyzer (PFA 100) to quantify the effect of low dose aspirin in patients with ischemic heart disease. Anaesthesia 2005; 60: 1173–1178.Google Scholar
6. Valles, J, Santos, MT, Aznar, J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350–355.Google Scholar
7. Heistein, LC, Scott, WA, Zellers, TM, et al. Aspirin resistance in children with heart disease at risk for thromboembolism: prevalence and possible mechanisms. Pediatr Cardiol 2008; 29: 285–291.Google Scholar
8. Cholette, JM, Mamikonian, L, Alfieris, GM, Blumberg, N, Lerner, NB. Aspirin resistence following pediatric cardiac surgery. Thromb Res 2010; 126: 200–206.CrossRefGoogle ScholarPubMed
9. Toth, O, Calatzis, A, Penz, S, Losconczy, H, Siess, W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781–788.Google ScholarPubMed
10. Jambor, C, Weber, CF, Gerhard, K, et al. Whole blood multiple electrode aggregometry is a reliable point-of-care test of aspirin-induced platelet dysfunction. Anesth Analg 2009; 109: 25–31.CrossRefGoogle ScholarPubMed
11. Paniccia, R, Antonucci, R, Maggini, N, et al. Assessement of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009; 131: 834–842.CrossRefGoogle ScholarPubMed
12. Velik-Salchner, C, Maier, S, Innerhofer, P, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth Analg 2008; 107: 1798–1806.Google Scholar
13. von Pape, KW, Dzijan-Horn, M, Bohner, J, Spannagl, M, Weisser, H, Calatzis, A. Control of aspirin in chronic cardiovascular patients using two whole blood platelet function assays-PFA-100® and Multiplate® . Hämostaseologie 2007; 27: 155–160.Google Scholar
14. Wells, WJ, Yu, RJ, Batra, AS, Monforte, H, Sintek, C, Starnes, VA. Obstruction in modified Blalock shunts: a quantitative analysis with clinical correlation. Ann Thorac Surg 2005; 79: 2072–2076.CrossRefGoogle ScholarPubMed
15. Monagle, P, Chalmers, E, Chan, A, et al. Antithrombotic therapy in neonates and children. Chest 2008; 133 (Suppl. 6): 887S–968S.CrossRefGoogle ScholarPubMed
16. Israels, SJ, Michelson, AD. Antiplatelet therapy in children. Thromb Res 2006; 118: 75–83.CrossRefGoogle ScholarPubMed
17. Gross, S, Keefer, V, Liebman, J. The platelets in cyanotic congenital heart disease. Pediatrics 1968; 42: 651–658.CrossRefGoogle ScholarPubMed
18. Waldman, JD, Czapek, EE, Paul, MH, Schwartz, AD, Levin, DL, Schindler, S. Shortened platelet survival in cyanotic heart disease. J Pediatr 1975; 87: 77–79.Google Scholar
19. Goldschmidt, B, Sorland, SJ. The young platelet population in children with cyanotic congenital heart disease. Thromb Haemost 1976; 35: 342–349.Google Scholar
20. Heying, R, Oeveren, W, Wilhelm, S, et al. Children undergoing cardiac surgery for complex cardiac defects show imbalance between pro-and anti-thrombotic activity. Crit Care 2006; 10: R165.CrossRefGoogle ScholarPubMed
21. Hashimoto, K, Yamagishi, M, Sasaki, T, Nakano, M, Kurosawa, H. Heparin and Antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994; 58: 799–805.Google Scholar
22. Chan, AK, Leaker, M, Burrows, FA, et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost 1997; 77: 270–277.Google Scholar
23. Siller-Matula, JM, Gouya, G, Wolzt, M, Jilma, B. Cross validation of the multiple electrode aggregometry, a prospective trial in healthy volunteers. Thromb Haemost 2009; 102: 397–403.CrossRefGoogle ScholarPubMed
24. Halimeh, S, Angelis, G, Sander, A, et al. Multiplate whole blood impedance point of care aggregometry: preliminary reference values in healthy infants, children and adolescents. Klin Padiatr 2010; 222: 158–163.CrossRefGoogle ScholarPubMed
25. Rahe-Meyer, N, Winterhalter, M, Hartmann, J, et al. An evaluation of cycloooxygenase-1 inhibition before coronary artery surgery: aggregometry versus patient self-reporting. Anesth Analg 2008; 107: 1791–1797.CrossRefGoogle Scholar